Literature DB >> 24841158

Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.

Iman A Abd El Gawad1, Ghada I Mossallam2, Noha H Radwan3, Heba M Elzawahry4, Niveen M Elhifnawy5.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is usually asymptomatic in the early stage and does not show elevated alpha-feto protein (AFP). AFP shows 60-80% sensitivity in diagnosing HCC. Glypican3 (GPC-3) is an oncofetal protein that is only detected in HCC cells but not in benign liver tissues, while Carcinoembryonic antigen (CEA) is expressed in various neoplasms including HCC. Although, it is not specific for HCC. Prothrombin induced by vitamin K absence-II (PIVKA-II) is an abnormal prothrombin protein that is increased in the serum of HCC patients. It has higher sensitivity and specificity compared to AFP. The aim of this study is to compare the clinical utility of PIVKA-II with GPC-3, AFP and CEA in diagnosing HCC. PATIENTS AND METHODS: This study included 40 patients with HCC, 10 patients with cirrhosis as a benign control group, and 10 apparently healthy volunteers as normal controls. Serum samples were subjected to routine laboratory investigations, measurement of CEA, AFP using MEIA technique (Axsym), glypican3, and PIVKA-II using ELISA technique in the sera of all patients and controls.
RESULTS: All markers showed the highest results in the HCC group. Higher concentrations of PIVKA-II were detected in patients with splenomegaly, and in tumors with size (>3cm). Combination of Glypican-3 and PIVKA-II showed the highest sensitivity, while GPC-3 alone and combination of GPC-3 and AFP showed the highest specificity to differentiate HCC from liver cirrhosis and normal controls. GPC-3, PIVKAII, and combination of both showed the highest sensitivity, while GPC-3 alone showed the highest specificity to differentiate HCC from liver cirrhosis.
CONCLUSION: Glypican-3 is the only oncofetal antigen that showed comparable high diagnostic accuracy as PIVKA-II in diagnosing HCC among Egyptian patients.
Copyright © 2014. Production and hosting by Elsevier B.V.

Entities:  

Keywords:  HCC; Oncofetal antigens; PIVKA-II

Mesh:

Substances:

Year:  2014        PMID: 24841158     DOI: 10.1016/j.jnci.2014.01.001

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  11 in total

Review 1.  Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.

Authors:  Yukihiro Haruyama; Hiroaki Kataoka
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas

Authors:  Sherif El-Saadany; Taher El-Demerdash; Amal Helmy; Wael Wahid Mayah; Boshra El-Sayed Hussein; Mohammed Hassanien; Nehal Elmashad; Mahmoud Ali Fouad; Eman Ahmed Basha
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27

3.  PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.

Authors:  Sarka Svobodova; Marie Karlikova; Ondrej Topolcan; Ladislav Pecen; Martina Pestova; Otto Kott; Vladislav Treska; David Slouka; Radek Kucera
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

4.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

5.  Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.

Authors:  Yejoo Jeon; Eun Sun Jang; Yun Suk Choi; Jin-Wook Kim; Sook-Hyang Jeong
Journal:  Clin Mol Hepatol       Date:  2016-09-25

6.  Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study.

Authors:  Huaping Chen; Siyuan Chen; Shan Li; Zhijian Chen; Xuan Zhu; Meiyu Dai; Lingxi Kong; Xiaodan Lv; Zhili Huang; Xue Qin
Journal:  Oncotarget       Date:  2017-08-07

Review 7.  Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis.

Authors:  Tingting Sun; Yurong Tang; Diwen Sun; Qingao Bu; Peng Li
Journal:  Onco Targets Ther       Date:  2018-12-10       Impact factor: 4.147

8.  PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma.

Authors:  Tao Li; Yuanzi Yu; Juan Liu; Xiangguo Tian; Meng Kong; Lei Wu; Shaocan Tang; Shengqing Gu; Jingfang Zhao; Yi Cui; Jinhua Hu
Journal:  Infect Agent Cancer       Date:  2019-05-14       Impact factor: 2.965

9.  Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels.

Authors:  Wan-Ju Xu; Bao-Li Guo; Yu-Gang Han; Lei Shi; Wan-Shan Ma
Journal:  Tumour Biol       Date:  2014-09-12

10.  Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma.

Authors:  Xiumei Wang; Weiwei Zhang; Youde Liu; Wenjing Gong; Ping Sun; Xiangshuo Kong; Miaomiao Yang; Zhihua Wang
Journal:  Infect Agent Cancer       Date:  2017-08-23       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.